A crystallization method of β-nicotinamide mononucleotide

By applying voltage and stirring during the crystallization of β-nicotinamide single nucleotides, combined with ethanol cooling and electric field, the problem of low bulk density of β-nicotinamide single nucleotides in the prior art is solved, and a high bulk density is obtained flake crystals are suitable for downstream processing and reduce production costs.

CN115894586BActive Publication Date: 2024-12-03SHENZHEN READLINE BIOTECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202211618995.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-12
Publication Date
2024-12-03
Estimated Expiration
2042-12-12

AI Technical Summary

Technical Problem

The crystals produced by the existing β-nicotinamide single nucleotide crystallization method are fine needle-like particles, resulting in low bulk density, increasing downstream processing difficulty, and methods that increase bulk density such as tablet granulation will reduce stability and Increase production costs.

Method used

The β-nicotinamide single nucleotide crystallization stock solution is added to ethanol under the conditions of applying voltage and stirring, and anhydrous ethanol is added during the crystallization process and the solution temperature is reduced. The electric field is used to change the molecular distribution and orientation, and the comparison is obtained by changing the molecular distribution and orientation. Large-sized sheet crystals, thereby increasing bulk density.

Benefits of technology

A high bulk density β-nicotinamide single nucleotide crystal is achieved, which is suitable for downstream processing, reduces production costs and improves the stability of product quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115894586B_ABST
    Figure CN115894586B_ABST
Patent Text Reader

Abstract

The present invention provides a method for crystallizing β-nicotinamide mononucleotide, comprising: adding ethanol to a β-nicotinamide mononucleotide crystal stock solution under conditions of applying voltage and stirring to crystallize. Compared with the prior art, the present invention provides the supersaturation required for crystallization by adding anhydrous ethanol to a high-concentration β-nicotinamide mononucleotide solution and lowering the solution temperature, and applies an electric field to change the distribution and orientation of β-nicotinamide mononucleotide crystals and β-nicotinamide mononucleotide molecules in a crystallization container during crystallization. After the electric field is applied, the effect of the electric field is stronger than the charge effect between β-nicotinamide mononucleotide molecules, thereby shielding the effect of the charge effect between β-nicotinamide mononucleotide molecules on the crystallization of β-nicotinamide mononucleotide, thereby obtaining crystals of larger size, making the crystals have a higher bulk density, being more suitable for processing by downstream enterprises, and also being conducive to reducing the production cost of the entire production chain, and the obtained product quality is more stable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and in particular relates to a crystallization method of β-nicotinamide mononucleotide. Background Art

[0002] β-Nicotinamide mononucleotide is abbreviated as NMN, which is a small biological molecule widely present in nature. In the human body, NMN is the direct precursor of NAD+, and NAD+ is an extremely important active substance in the human body. It exists in every cell of the human body and participates in thousands of reactions. It is also an indispensable active substance in cell metabolism and an important support for cells to maintain vitality. During the aging process of the human body, the decline in NAD+ levels in the body is considered to be an important cause of disease, so increasing the level of NAD+ in the body is an important way to fight aging. However, it is difficult for the human body to directly ingest NAD+, so increasing the concentration of NAD+ in the body by taking NMN has become an important method of anti-aging.

[0003] But no matter what method is used to produce NMN, it is necessary to purify and remove impurities to obtain NMN finished products with qualified purity. The main purification methods of NMN in the industry are ion exchange, membrane filtration, and crystallization. Among them, crystallization is the most important step in the NMN purification process. The crystallization step determines the product purity, product appearance, and product bulk density. The current method of NMN crystallization in the industry is mainly the dissolution crystallization method at low temperature using water as a good solvent and ethanol as a poor solvent to reduce the solubility of NMN. The NMN crystals produced by this method are mainly small needle-shaped particles (such as Figure 1 As shown in the figure, the bulk density is low (less than 0.25 g / ml), which is easily blown up by airflow, increasing the difficulty for downstream processing companies to process NMN finished preparations. In addition, too low a bulk density will also lead to a decrease in the NMN content in oral tablets (some enteric-coated capsules have limited volume). In addition, the main method for increasing bulk density in the industry is tableting and granulation, but tableting and granulation will reduce the stability of NMN and increase production costs. Summary of the invention

[0004] In view of this, the technical problem to be solved by the present invention is to provide a method for crystallizing β-nicotinamide mononucleotide, wherein the β-nicotinamide mononucleotide crystals obtained by the method are thicker sheets with higher bulk density.

[0005] The present invention provides a method for crystallizing β-nicotinamide mononucleotide, comprising:

[0006] The β-nicotinamide mononucleotide crystal stock solution was cooled and crystallized by adding ethanol under the conditions of applying voltage and stirring.

[0007] Preferably, after cooling, β-nicotinamide mononucleotide solid is added as a seed crystal to guide crystallization; the volume ratio of the mass of the β-nicotinamide mononucleotide solid to the β-nicotinamide mononucleotide crystal stock solution is (0.01-0.05) g:10 mL.

[0008] Preferably, ethanol is added after cooling and crystallizing for 1 to 5 hours, and crystallization is continued after the addition is completed.

[0009] Preferably, the rate of adding ethanol is 5 mL / h; and the volume ratio of the added ethanol to the β-nicotinamide mononucleotide crystal stock solution is 0.8:1.

[0010] Preferably, after continuing crystallization for 1 hour, the temperature is lowered and crystallization is continued.

[0011] Preferably, the temperature of the continued cooling crystallization is 3°C; and the time of the continued cooling crystallization is 1 hour.

[0012] Preferably, the concentration of the β-nicotinamide mononucleotide crystallization stock solution is 220-300 g / L; the pH value of the β-nicotinamide mononucleotide crystallization stock solution is 1.5-4.

[0013] Preferably, the intensity of the voltage is 10-50V; the direction of the voltage is switched every 1s.

[0014] Preferably, the volume ratio of the ethanol to the β-nicotinamide mononucleotide crystallization stock solution is 2:10; and the temperature of the cooling crystallization is 10°C.

[0015] The present invention also provides a β-nicotinamide mononucleotide crystal obtained by the above crystallization method, wherein the β-nicotinamide mononucleotide crystal is in a flake shape; and the bulk density of the β-nicotinamide mononucleotide crystal is greater than or equal to 0.4 g / mL.

[0016] The present invention provides a method for crystallizing β-nicotinamide mononucleotide, comprising: adding ethanol to a β-nicotinamide mononucleotide crystal stock solution under the conditions of applying voltage and stirring to cool and crystallize. Compared with the prior art, the present invention provides the supersaturation required for crystallization by adding anhydrous ethanol to a high-concentration β-nicotinamide mononucleotide solution and lowering the solution temperature, and applies an electric field to change the distribution and orientation of β-nicotinamide mononucleotide crystals and β-nicotinamide mononucleotide molecules in a crystallization container during crystallization. After the electric field is applied, the effect of the electric field is stronger than the charge effect between β-nicotinamide mononucleotide molecules, thereby shielding the effect of the charge effect between β-nicotinamide mononucleotide molecules on the crystallization of β-nicotinamide mononucleotide, thereby obtaining larger crystals, making the crystals have a higher bulk density, and are more suitable for processing by downstream enterprises, and are also conducive to reducing the production cost of the entire production chain, and the obtained product quality is more stable. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a microscope photo of NMN crystals produced by existing methods;

[0018] Figure 2 It is a schematic diagram of the structure of the crystallization equipment used in Examples 1 to 6 of the present invention;

[0019] Figure 3 This is a microscope photo of the NMN crystals obtained in Example 1 of the present invention;

[0020] Figure 4 This is a microscope photo of the NMN crystals obtained in Example 2 of the present invention;

[0021] Figure 5 This is the X-ray diffraction pattern of the NMN crystal obtained in Example 2 of the present invention;

[0022] Figure 6 is the X-ray diffraction pattern of commercially available NMN;

[0023] Figure 7 This is a microscope photo of the NMN crystals obtained in Example 3 of the present invention;

[0024] Figure 8 This is a microscope photograph of the NMN crystals obtained in Example 4 of the present invention;

[0025] Fig. 9 This is a microscope photograph of the NMN crystals obtained in Example 5 of the present invention;

[0026] Fig.10 This is a microscope photograph of the NMN crystals obtained in Example 6 of the present invention;

[0027] Fig.11 This is the X-ray diffraction pattern of the NMN crystal obtained in Example 6 of the present invention. DETAILED DESCRIPTION

[0028] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0029] The present invention provides a method for crystallizing β-nicotinamide mononucleotide, comprising: adding ethanol to a β-nicotinamide mononucleotide crystallization stock solution under conditions of applying voltage and stirring, and then cooling and crystallizing.

[0030] The present invention has no particular limitation on the sources of all raw materials, and any raw materials available on the market can be used.

[0031] The β-nicotinamide mononucleotide crystallization stock solution is added with ethanol to cool and crystallize under the conditions of applying voltage and stirring; the β-nicotinamide mononucleotide crystallization stock solution is preferably an aqueous solution of β-nicotinamide mononucleotide crystals; the concentration of the β-nicotinamide mononucleotide crystallization stock solution is preferably 220-300 g / L; the pH value of the β-nicotinamide mononucleotide crystallization stock solution is preferably 1.5-4, more preferably 2-4, more preferably 2.5-3.5, and most preferably 3; in the embodiments provided by the present invention, the pH value of the β-nicotinamide mononucleotide crystallization stock solution is specifically 1.7, 2.5, 3 or 3.6; the intensity of the voltage is preferably 30 ~50V, more preferably 40V; in the embodiment provided by the present invention, the intensity of the voltage is specifically 30V, 40V or 50V; the direction of the voltage is switched once every 1s; the stirring speed is preferably 150rpm; the volume ratio of the added ethanol to the β-nicotinamide mononucleotide crystallization stock solution is preferably 2:10; the temperature of the cooling crystallization is preferably 10°C; after cooling, β-nicotinamide mononucleotide solid is preferably added as a seed to guide crystallization; the mass ratio of the β-nicotinamide mononucleotide solid to the volume ratio of the β-nicotinamide mononucleotide crystallization stock solution is preferably 0.02g:10mL; the cooling crystallization time is preferably 3h.

[0032] According to the present invention, after cooling and crystallizing, ethanol is preferably added in a stream; the rate of adding ethanol in a stream is preferably 5 mL / h; the volume ratio of the added ethanol to the volume of the β-nicotinamide mononucleotide crystallization stock solution is preferably 0.8: 1. Supersaturation can be slowly provided by adding ethanol in a stream to prevent explosion.

[0033] After the addition of ethanol is completed, crystallization is continued; the time for the continued crystallization is preferably 1 hour. During this period of continued crystallization, the supersaturation can be consumed to prevent the crystals from precipitating too quickly in the next step of cooling and crystallization.

[0034] After the continued crystallization, preferably the crystallization is continued by cooling down to obtain β-nicotinamide mononucleotide crystals; the temperature of the continued crystallization is preferably 3° C.; the time of the continued crystallization is preferably 1 hour. The crystallization yield can be increased by continuing the crystallization by cooling down.

[0035] The present invention provides the supersaturation required for crystallization by adding anhydrous ethanol to a high-concentration β-nicotinamide mononucleotide solution and lowering the solution temperature. During crystallization, an electric field is applied to change the distribution and orientation of β-nicotinamide mononucleotide crystals and β-nicotinamide mononucleotide molecules in a crystallization container. After the electric field is applied, the effect of the electric field is stronger than the charge effect between β-nicotinamide mononucleotide molecules, thereby shielding the influence of the charge effect between β-nicotinamide mononucleotide molecules on the crystallization of β-nicotinamide mononucleotide, thereby obtaining crystals of larger size, making the crystals have a higher bulk density, being more suitable for processing by downstream enterprises, and being conducive to reducing the production cost of the entire production chain, and obtaining a more stable product quality.

[0036] The present invention also provides a β-nicotinamide mononucleotide crystal obtained by the above crystallization method; the β-nicotinamide mononucleotide crystal is in a flake shape; and the bulk density of the β-nicotinamide mononucleotide crystal is greater than or equal to 0.4 g / mL.

[0037] In the present invention, the bulk density of the β-nicotinamide mononucleotide crystals is preferably 0.4 to 0.7 g / mL, more preferably 0.4 to 0.65 g / mL, and even more preferably 0.45 to 0.62 g / mL.

[0038] In order to further illustrate the present invention, a crystallization method of β-nicotinamide mononucleotide provided by the present invention is described in detail below in conjunction with examples.

[0039] The reagents used in the following examples are all commercially available; the bulk density test method in the examples is to take 8 g of the finished product and pour it into a 25 mL measuring cylinder, read the volume of the finished product, and obtain the bulk density of the finished product by dividing the weight by the volume.

[0040] Example 1

[0041] Towards Figure 2 The device shown in the figure (the diameter of the crystallization kettle is 6 cm, the electrode plates are wrapped with insulating material, and the two electrode plates are 8 cm apart. The direction of the electric field will change with the process. Figure 2 Add 50mL of NMN crystallization solution to the solution (just illustrate the direction of the electric field from left to right). The concentration of NMN crystallization solution is 300g / L, and the pH is 3. Turn on the stirring, the stirring speed is 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 30V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h. After cooling to 3°C, continue crystallization for 1h. Take a sample and observe the crystal shape under a microscope. Figure 3 The final product bulk density is 0.45g / mL.

[0042] Example 2

[0043] Towards Figure 2 Add 50mL of NMN crystallization stock solution to the device shown. The concentration of NMN crystallization stock solution is 220g / L and the pH is 3. Turn on stirring at a speed of 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 40V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h. After cooling to 3°C, continue crystallization for 1h. Take a sample and observe the crystal shape under a microscope to obtain Figure 4 The final bulk density of the finished product is 0.55g / ml.

[0044] The NMN crystals obtained in Example 2 were analyzed by X-ray diffraction, and the X-ray diffraction pattern was as follows: Figure 5 shown.

[0045] The commercially available NMN was analyzed using X-rays, and its X-ray diffraction pattern was obtained as follows: Figure 6 shown.

[0046] Example 3

[0047] Towards Figure 2 Add 50mL of NMN crystallization stock solution to the device shown. The concentration of NMN crystallization stock solution is 220g / L and the pH is 3. Turn on stirring at a speed of 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 50V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h. After cooling to 3°C, continue crystallization for 1h. Take a sample and observe the crystal shape under a microscope to obtain Figure 7 The final product bulk density is 0.49g / mL.

[0048] Example 4

[0049] Towards Figure 2Add 50mL of NMN crystallization stock solution to the device shown. The concentration of NMN crystallization stock solution is 220g / L and the pH is 2.5. Turn on stirring at a speed of 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 40V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h, cool to 3°C and continue crystallization for 1h, take a sample and observe the crystal shape under a microscope to obtain Figure 8 The final product bulk density is 0.42g / mL.

[0050] Example 5

[0051] Towards Figure 2 Add 50mL of NMN crystallization stock solution to the device shown. The concentration of NMN crystallization stock solution is 220g / L and the pH is 3.6. Turn on stirring at a speed of 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 40V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h. After cooling to 3°C, continue crystallization for 1h. Take a sample and observe the crystal shape under a microscope to obtain Fig. 9 The final product bulk density is 0.48g / mL.

[0052] Example 6

[0053] Towards Figure 2 Add 50mL of NMN crystallization stock solution to the device shown. The concentration of NMN crystallization stock solution is 220g / L and the pH is 1.7. Turn on stirring at a speed of 150rpm, add 10mL of anhydrous ethanol, cool to 10°C, and use an external power supply to form a 40V potential difference between electrode plate 1 and electrode plate 2. The direction of the potential difference switches once per second. Add 0.1g of NMN solid to start crystallization. After crystallization for 3h, add 40mL of ethanol to the crystallization equipment at a flow rate of 5mL / h. After the addition of ethanol is completed, continue crystallization for 1h. After cooling to 3°C, continue crystallization for 1h. Take a sample and observe the crystal shape under a microscope to obtain Fig.10 The final product bulk density is 0.36g / mL.

[0054] The NMN crystals obtained in Example 6 were analyzed by X-ray diffraction, and the X-ray diffraction pattern was as follows: Fig.11 shown.

Claims

1. A method for crystallizing β-nicotinamide mononucleotide, It is characterized in that include: Add ethanol to cool down the β-nicotinamide mononucleotide crystal stock solution under the conditions of applying voltage and stirring to crystallize; The concentration of the β-nicotinamide mononucleotide crystallization stock solution is 220-300 g / L; the pH value of the β-nicotinamide mononucleotide crystallization stock solution is 1.5-4; The intensity of the voltage is 10 to 50 V; the direction of the voltage is switched every 1 second; After cooling, β-nicotinamide mononucleotide solid is added as a seed to guide crystallization; the volume ratio of the mass of the β-nicotinamide mononucleotide solid to the β-nicotinamide mononucleotide crystal stock solution is (0.01-0.05) g:10 mL.

2. The crystallization method according to claim 1, It is characterized in that After cooling and crystallizing for 1 to 5 hours, ethanol is added in a stream, and crystallization continues after the addition is completed.

3. The crystallization method according to claim 2, It is characterized in that The rate of the ethanol addition was 5 mL / h; the volume ratio of the ethanol addition to the β-nicotinamide mononucleotide crystal stock solution was 0.8:

1.

4. The crystallization method according to claim 2, It is characterized in that After continuing crystallization for 1 hour, continue to cool and crystallize.

5. The crystallization method according to claim 4, It is characterized in that The temperature of the continued cooling crystallization is 3°C; the time of the continued cooling crystallization is 1 hour.

6. The crystallization method according to claim 1, It is characterized in that The volume ratio of the ethanol to the β-nicotinamide mononucleotide crystallization stock solution is 2:10; and the temperature of the cooling crystallization is 10°C.

Citation Information

Patent Citations

  • Crystallization method of nicotinamide mononucleotide

    CN113402570A